Further peer-reviewed evidence that using Cellvizio as an adjunct to the standard of care can significantly improve the speed and accuracy of...
Third Quarter Total Sales Increase 13% year-over-year; U.S. Sales up 7% First Nine Months Total Sales Decrease 28% year-over-year; Significant...
1H’20 financial results driven primarily by a 10% reduction in total operating expenses (without COGS) and a 17% reduction in net loss...
Company to host business update conference call on Tuesday, September 22, 2020, at 6:00 PM CEST (Paris time) / 1:00 PM (New York time) Mauna...
Mauna Kea Technologies announced today the appointment of Claire Biot, Ph.D., as an Independent Director, effective immediately. Dr Claire Biot...
First Half of 2020 total sales down 47%; U.S. sales down 19% Second Quarter total sales down 72%; U.S. sales down 47% Sufficient...
Mauna Kea Technologies announced that it has received financing approvals from BNP Paribas and Bpifrance for a total of €4 million in...
Mauna Kea Technologies announced it has drawn down the €6m second tranche of their €22.5 million loan agreement concluded on 20 June...
The Cellvizio® 100 series system with the AQ-Flex™ 19 Confocal Miniprobe™ will be used for the assessment of peripheral lung...
Analysis by SAGES Technology and Value Assessment Committee concludes that Cellvizio® has an excellent safety profile and increases the...
READ THE PRESS RELEASE
Mauna Kea Technologies announced it has obtained confirmation from the EIB of its consent to disburse the second tranche of their €22.5...
